讲师、医学博士、硕士生导师，同济大学附属上海市第四人民医院肿瘤科副主任医师，科主任。长期从事恶性肿瘤的综合治疗，尤其免疫药物和靶向药物的治疗。

现任中国医药教育协会疑难肿瘤专业委员会常务委员、中国抗癌协会中西医整合肿瘤专业委员会委员、长三角肿瘤专科联盟理事、上海市中西医结合学会肿瘤微创专业委员会常务委员、上海市抗癌协会肿瘤生物治疗专业委员会委员、上海市抗癌协会肿瘤药物临床研究专业委员会委员等。

Lecturer, medical doctor, master's supervisor, deputy chief physician and chief of Oncology Department of Shanghai Fourth People's Hospital Affiliated to Tongji University. He has been engaged in the comprehensive treatment of malignant tumors for a long time, especially the treatment of immune drugs and targeted drugs.

He is currently a standing member of the difficult tumor Professional Committee of the Chinese Medical Education Association, a member of the professional committee of Integrated Chinese and Western medicine of the Chinese Anti-Cancer Association, a director of the Yangtze River Delta cancer specialist alliance, a standing member of the tumor minimally invasive Professional Committee of the Shanghai Society of Integrated Chinese and Western medicine, a member of the tumor biotherapy Professional Committee of the Shanghai anti-cancer association, and a member of the tumor drug clinical research professional committee of the Shanghai anti-cancer association.

主持并完成上海市卫健委课题2项、虹口区科委课题1项、吴阶平医学课题1项，在研上海市第四人民医院启动课题2项(科研经费100万)。作为第一作者/通讯作者发表SCI收录论文10篇，中文核心期刊21篇，包括中华系列3篇。

Presided over and completed 2 projects of Shanghai Municipal Health Commission, 1 project of Hongkou District Science and Technology Commission, 1 project of Wu Jieping's medical science, and 2 startup projects of Shanghai Fourth People's Hospital (scientific research fund of 1 million). As the first author / corresponding author, he published 10 papers included in SCI, 21 Chinese core journals, including 3 Chinese series.

[1] Siyue Zhang#; Fangyuan Xie#; Kaichun Li#; He Zhang#; You Yin#; Yuan Yu; Guangzhao Lu; Shihao Zhang; Yan Wei; Ke Xu; Yan Wu; Hong Jin; Lan Xiao; Leilei Bao; Yulin Li*; Ying Lu*; Jie Gao*; Gold Nanoparticle-Directed Autophagy Intervention for Antitumor Immunotherapy via Inhibiting Tumor Associated Macrophage M2 Polarization, Acta Pharmaceutica Sinica B, 2022, 12(7): 3124-3138. <2022 IF: 14.903>

[2] Xinxin Wang#; Haitao Gu#; Kaichun Li#; Jiayun Lin; Yiming Zhu; Wensheng Deng*; DPP4 inhibitor reduces portal hypertension in cirrhotic rats by normalizing arterial hypocontractility, Life Sciences, 2021, 284: 119895. <2022 IF: 6.780>

[3] Kaichun Li*; Liying Pang; Xiaorong Pan; Shaonan Fan; Xinxin Wang; Qiaoyun Wang; Ping Dai; Wei Gao*; Jie Gao*; GE11 Modified PLGA/TPGS Nanoparticles Targeting Delivery of Salinomycin to Breast Cancer Cells, Technology in Cancer Research & Treatment, 2021, 20: 15330338211004954. <2021 IF: 3.399>

[4] Kaichun Li*; Qiaoyun Wang; Yanyan Lu; Xiaorong Pan; Long Liu; Shiyu Cheng; Bingxiang Wu; Zongchang Song*; Wei Gao*; Machine learning based tissue analysis reveals Brachyury has a diagnosis value in breast cancer, Bioscience Reports, 2021, 41(4): BSR20203391. <2022 IF: 3.976>

[5] Qingliang Fang#*; Kaichun Li#; Lei Wang; Xianglian Gu; Renjie Song; Song Lu; Targeted Inhibition of CCL22 by miR-130a-5p Can Enhance the Sensitivity of Cisplatin-Resistant Gastric Cancer Cells to Chemotherapy, Cancer Management and Research, 2020, 12: 3865-3875. <2022 IF: 3.602>

[6] Bing Dan#; Jie Luo#; Kaichun Li*; Shiyu Chen; Prognostic Value of miR-375 for Survival Outcomes in Various Cancers: A Systematic Review and Meta-Analysis, Oncology Research and Treatment, 2018, 41(1-2): 47-50. <2022 IF: 2.844>

[7] Kaichun Li; Mingzhen Ying; Dan Feng; Jie Du; Shiyu Chen; Bing Dan; Cuihua Wang; Yajie Wang*; Brachyury promotes tamoxifen resistance in breast cancer by targeting SIRT1, Biomedicine & Pharmacotherapy, 2016, 84: 28-33. <2022 IF: 7.419>

[8] Kaichun Li; Mingzhen Ying; Dan Feng; Yan Chen; Jingwen Wang; Yajie Wang*; SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury, Oncology Reports, 2016, 35: 2405-2412. <2022 IF: 4.136>

[9] Kaichun Li; Mingzhen Ying; Dan Feng; Jie Du; Shiyu Chen; Bing Dan; Cuihua Wang; Yajie Wang*; Fructose-1,6-bisphosphatase is a novel regulator of Wnt/β-Catenin pathway in breast cancer, Biomedicine & Pharmacotherapy, 2016, 84: 1144-1149. <2022 IF: 7.419>

[10] Kaichun Li; Jin Li*; Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application, Gastroenterology Research and Practice, 2016, 2016: 4105615. <2022 IF: 1.919>

[11] 李开春; 程诗宇; 杜杰; 李进*; 转移性或局部晚期胃癌的二线治疗选择, 中华肿瘤杂志, 2016, 38(10): 721-724. < 专题综论>

[12] 李开春*; 陈佳艳; 老年晚期肺癌患者药物治疗的选择, 中华肿瘤杂志, 2015, 37(10): 721-724. < 专题综论>

[13] 李开春; 曾晓颖; 匡春香; 江玉波; 戴兆云*; 碘化亚油酸及5-氟尿嘧啶酯抑制肝细胞癌生长的初步研究, 中华肝脏病杂志, 2013, 21(5): 372-375. < 论著>